The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell LymphomaMatthew J. Maurer,Arushi Khurana,Umar Farooq,Jason T. Romancik,Jonathan W. Friedberg,Izidore S. Lossos,Brad S. Kahl,Peter Martin,Dai Chihara,Andrew L. Feldman,Sergei Syrbu,David L Jaye,Elliot Cahn,Thomas M. Habermann,Brian K. Link,James R. Cerhan,Christopher R. Flowers,Loretta J. Nastoupil,Grzegorz S. NowakowskiBlood(2023)引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要